Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of
Major ARBs to Impact the Market
Research, a leading business intelligence provider, has released its latest research,
“Antihypertensives Market to 2016 - Generic Erosion Following Patent Expiry of Major ARBs
to Impact the Market”. The report provides in-depth analysis of the unmet needs, drivers
and barriers that affect the global antihypertensive market.
To Brows a Full Report with Toc: http://www.researchmoz.us/antihypertensivesmarket-to-2016-generic-erosion-following-patent-expiry-of-major-arbs-to-impact-themarket-report.html
The report analyzes the markets for antihypertensive disorders in the US, the top five
markets in Europe (the UK, Germany, France, Italy and Spain), and Japan. Treatment usage
patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well
as the leading therapeutic segments.
Furthermore, the report provides competitive benchmarking for the leading companies and
analyzes the mergers, acquisitions and licensing agreements that shape the global
The scope of this report includes:
Annualized market data for the antihypertensive disorders market from 2002 to 2009,
forecast forward to 2016.
Analysis of the leading therapeutic segments, including hypertension and PAH.
Analysis of the antihypertensive disorders market in the leading geographies of the world,
which include the US, the UK, Germany, France, Italy, Spain and Japan.
Market characterization of the antihypertensive disorders market, including market size,
annual cost of therapy and treatment usage patterns.
Key drivers and barriers that have a significant impact on the market.
Coverage of pipeline molecules in various phases of drug development.
Competitive benchmarking of leading companies. The key companies studied in this report
are Novartis, Merck, AstraZeneca, United Therapeutics, Actelion and Pfizer.
Key M&A activities,...